Hebert Alberto Vargas
Memorial Sloan Kettering Cancer Center
CancerInternal medicineRadiologySurgeryPathologyMagnetic resonance imagingOncologyRetrospective cohort studyStage (cooking)Positron emission tomographyBiopsyProstateDiseaseProstatectomyProstate cancerBladder cancerMr imagingNuclear medicineIn patientRadiation therapyMedicine
176Publications
38H-index
4,913Citations
Publications 175
Newest
Source
#1Jeeban Paul Das (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 3
#2Hebert Alberto Vargas (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 38
Last. Gary A. Ulaner (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 12
view all 5 authors...
Our objective was to evaluate the impact of 18F-FDG PET CT on the management of urachal adenocarcinoma (UrC-ADC). Methods: A retrospective analysis of patients with UrC-ADC from 2001 to 2019 at Memorial Sloan Kettering was performed. Mayo stage before 18F-FDG PET/CT, rate of detection of the primary malignancy and metastases on 18F-FDG PET/CT, Mayo stage after 18F-FDG PET/CT, and change in patient management were determined. Results: Of 21 patients with UrC-ADC before 18F-FDG PET/CT, Mayo stagin...
1 CitationsSource
#1Giuseppe Petralia (IEO: European Institute of Oncology)H-Index: 23
#2Dow-Mu Koh (University of Milan)
Last. Anwar R. PadhaniH-Index: 91
view all 12 authors...
This Oncologically Relevant Findings Reporting and Data System, or ONCO-RADS, consensus on whole-body MRI for cancer screening proposes standard protocols for higher-risk individuals.
1 CitationsSource
#1Sangwon Han (UOU: University of Ulsan)H-Index: 10
#2Sungmin Woo (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 26
Last. Hebert Alberto Vargas (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 38
view all 8 authors...
Prostate-specific membrane antigen positron emission tomography (PSMA PET) has recently gained interest as a promising tool for treatment response evaluation in metastatic castration-resistant prostate cancer (CRPC). We performed a systematic review and meta-analysis assessing the concordance between response evaluation using PSMA PET and serum prostate-specific antigen (PSA) level after systemic treatment and the association between PSMA PET and overall survival in metastatic CRPC patients. Pub...
Source
#1Andreas Wibmer (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 21
#2Joshua Chaim (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 10
Last. Hebert Alberto Vargas (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 38
view all 14 authors...
PURPOSE We investigated whether T2-weighted magnetic resonance imaging findings could improve upon established prognostic indicators of metastatic disease and cancer specific survival. MATERIALS AND METHODS For a cohort of 3,406 consecutive men who underwent prostate magnetic resonance imaging before definitive prostatectomy (2,160) or radiotherapy (1,246) between 2001 and 2006, T2-weighted MRI exams were retrospectively interpreted and categorized as I) no focal suspicious lesion, II) organ con...
1 CitationsSource
#1Sang-gyu Lee (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 7
#2Teja Muralidhar Kalidindi (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 4
Last. Steven M. Larson (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 135
view all 14 authors...
With the successful development and increased use of targeted radionuclide therapy for treating cancer comes the increased risk of radiation injury to bone marrow-both direct suppression and stochastic effects, leading to neoplasia. Herein, we report a novel radioprotector drug, a liposomal formulation of γ-tocotrienol (GT3), or GT3-Nano for short, to mitigate bone marrow radiation damage during targeted radionuclide therapy. Methods: GT3 was loaded into liposomes using passive loading. 64Cu-GT3...
Source
#1Elio Adib (Brigham and Women's Hospital)H-Index: 1
#1Elio Adib (Brigham and Women's Hospital)H-Index: 2
Last. David J. Kwiatkowski (Brigham and Women's Hospital)H-Index: 142
view all 19 authors...
Purpose This was a multicenter, histology-agnostic, single-arm prospective phase II trial of therapeutic activity of everolimus, an oral mTORC1 inhibitor, in patients with advanced solid tumors that harbored TSC1/TSC2 or MTOR mutations. Experimental design Patients with tumors with inactivating TSC1/TSC2 or activating MTOR mutations identified in any CLIA-certified laboratory were eligible. Patients were treated with everolimus 10mg once daily until disease progression or unacceptable toxicity. ...
Source
#1Ines Nikolovski (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 5
#2Maria I. Carlo (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 18
Last. Hebert Alberto Vargas (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 38
view all 4 authors...
BACKGOUND Fumarate hydratase-deficient renal cell carcinoma (FH-RCC) is a subtype of RCC that is increasingly recognized pathologically. The aim of this study was to evaluate the imaging features of FH-RCC on computed tomography (CT), magnetic resonance imaging (MRI), and fluorodeoxyglucose positron emission tomography (FDG PET), and to determine the pre-operative diagnostic potential of imaging. METHODS This single-site retrospective study included patients with histologically confirmed FH-RCC ...
Source
#1Gregory T. Chesnut (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 4
#2Amy Tin (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 9
Last. Behfar Ehdaie (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 28
view all 16 authors...
Abstract Background Salvage partial gland ablation (sPGA) has been proposed to treat some localized radiorecurrent prostate cancer. The role of prostate biopsy and magnetic resonance imaging (MRI) characteristics to identify patients eligible for sPGA is unknown. Objective To evaluate the ability of MRI and prostate biopsy characteristics to identify an index lesion suitable for sPGA and validate this selection using detailed tumor maps created from whole-mount slides from salvage radical prosta...
Source
#1Sungmin Woo (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 26
#2Hebert Alberto Vargas (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 38
Source